Estrella Immunopharma Overview
Latest ROE for Estrella Immunopharma: 134.74% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow134.74%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Estrella Immunopharma posts a ROE of 134.74%. That is above the sector sector average of -6.13%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a ROE near -6.13% is typical. Estrella Immunopharma's 134.74% is higher that level. That is roughly 2298.6% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Estrella Immunopharma's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 134.74%; use YoY and peer views to separate noise from signal.
Context for ESLA's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -6.13%), and (3) consistency with growth and profitability. This page covers the first two; Estrella Immunopharma's other metric pages and overview cover the third.
